Merkel cell carcinoma and the eye

Area of Science:

• Oncology
• Dermatology
• Ophthalmology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with rising incidence.
• Eyelid MCC is uncommon, often misdiagnosed, and presents unique diagnostic and management challenges.
• Despite rising cases, eyelid MCC exhibits a lower disease-specific mortality rate compared to other head and neck sites.

Purpose of the Study:

• To review the diagnosis, staging, and treatment of Merkel cell carcinoma of the eyelid.
• To highlight the importance of accurate diagnostic methods and prognostic indicators.
• To discuss current and emerging therapeutic strategies for eyelid MCC.

Main Methods:

• Review of current literature on eyelid Merkel cell carcinoma.
• Discussion of diagnostic techniques, including biopsy and immunohistochemistry (CK20, TTF-1).
• Analysis of staging methods (clinical, imaging, sentinel lymph node biopsy) and their prognostic value.

Main Results:

• Biopsy with immunohistochemistry is essential for MCC diagnosis.
• Pathologic staging provides more accurate prognosis prediction than clinical staging.
• Mohs micrographic surgery followed by adjuvant radiotherapy is a primary treatment modality.
• Immunotherapy is preferred over chemotherapy for advanced eyelid MCC.

Conclusions:

• Accurate diagnosis and staging are critical for managing eyelid MCC.
• Multidisciplinary treatment approaches, including surgery, radiotherapy, and immunotherapy, offer the best outcomes.
• Ongoing research into advanced therapies like immunotherapy is vital for improving survival rates.